A Study to Test GlaxoSmithKline's (GSK) Respiratory Syncytial Virus RSV Candidate Vaccine's Safety and Immune Response in Japanese Older Adults

NCT04090658 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Respiratory Syncytial Virus Infections

Interventions

BIOLOGICAL: RSV_PreF3 Vaccine (GSK3844766A) adjuvanted with AS01B
DRUG: Placebo

Sponsor

GlaxoSmithKline